

Special Issue

Advances in Understanding the Immune Network of Thyroid Cancers

Message from the Guest Editor

The importance of the immune system in the development of tumors and response to therapy has long been recognized. Mechanisms underlying these influences are now being elucidated for various human malignancies, including primary thyroid cancers.

Seminal works delineating the immune landscapes of differentiated, anaplastic, and poorly differentiated thyroid carcinomas, as well as clinical data suggesting promising results with immune checkpoint therapy in some patients with thyroid cancer emphasize the importance of understanding immune contributions to thyroid cancer development and therapeutic response.

We are pleased to invite authors to submit articles addressing the interaction of immune cells, cytokines, and lymph system to thyroid cancer establishment, aggressiveness, and response to therapies including radiation, immune checkpoint therapies, and other immunotherapies, as well as targeted therapies such as BRAF kinase inhibitors and MEK/MAPK pathway inhibitors. Original articles and review articles are welcome.

Guest Editor

Dr. Stephanie Markovina

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63108, USA

Deadline for manuscript submissions

closed (31 March 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/98077

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)